Who Should Not Take Wegovy for Weight Loss?

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Two groups are ruled out of Wegovy absolutely. According to the Wegovy prescribing information, the medication is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone who has had a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in the injection or the tablet. Those are the only two contraindications in the entire label. Everything else people commonly ask about — gallbladder disease, pancreatitis history, kidney problems, diabetic eye disease, thyroid nodules, being on insulin — sits in a different category. Those are warnings and precautions, meaning they change the conversation with your prescriber rather than automatically ending it.

What a Contraindication Actually Means

A contraindication is the strongest statement a label can make short of a market withdrawal. It says the risk of using the drug in that population is not outweighed by any expected benefit, so it should not be used at all. That is a categorically different instruction from a warning, which flags a known hazard that a clinician is expected to weigh, monitor for, and manage.

Wegovy's MTC and MEN 2 contraindication traces directly to its boxed warning. In rodents, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. Whether that translates to humans has not been determined, and because it has not been determined, the label excludes people whose personal or family history already places them in the population where such tumors occur. The exclusion is precautionary by design.

The second contraindication is more straightforward. If you have previously had a serious hypersensitivity reaction to semaglutide itself or to an inactive ingredient in the formulation, re-exposure is not appropriate. That history is something only you and your medical record can supply, which is why intake questionnaires ask about it in detail.

Pregnancy, Breastfeeding, and Planning a Pregnancy

Weight reduction is not a goal of pregnancy care. The label states plainly that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and it instructs that Wegovy be discontinued when a pregnancy is recognized for the weight-reduction indications. This is not a nuance to negotiate; it is a clear directive in the labeling.

Novo Nordisk also maintains a pregnancy exposure registry that monitors outcomes in women exposed to Wegovy during pregnancy, and the label encourages both patients and providers to contact it. The existence of that registry is a signal in itself: exposure during pregnancy is something the manufacturer is actively tracking because the human data are limited.

If you are pregnant, trying to conceive, or breastfeeding, this belongs at the very front of the conversation with your prescriber rather than as an afterthought at the end of an intake form.

The Conditions That Warrant Caution — Not Automatic Exclusion

Wegovy's warnings and precautions section runs from 5.1 through 5.10 and covers risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation.

Each of these describes a population that needs closer evaluation and monitoring. Someone with a history of pancreatitis, established gallbladder disease, advanced kidney impairment, or diabetic retinopathy is not automatically disqualified by the label — but a prescriber has to decide whether the benefit justifies the risk for that specific person, and what monitoring the decision requires. That determination cannot be made from an article, a symptom checker, or a marketing page.

It is worth noting what is not on that list any longer. Earlier versions of the label carried a subsection on suicidal behavior and ideation. It was removed in the 02/2026 revision, and section 5.10 is now pulmonary aspiration during general anesthesia or deep sedation. Any source still describing a suicidality warning in the Wegovy label is working from an outdated document.

Medication Combinations the Label Advises Against

The Wegovy label includes a Limitations of Use statement: concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. That covers stacking a weight-management semaglutide product on top of a diabetes semaglutide product, and it covers combining semaglutide with a different GLP-1 medication entirely.

Separately, the hypoglycemia warning is most relevant to people taking insulin or an insulin secretagogue such as a sulfonylurea. Adding a GLP-1 receptor agonist to those regimens can increase the risk of low blood sugar, and the label anticipates that background diabetes therapy may need to be reassessed by the prescriber. If you take insulin, that is a conversation to have before starting, not after.

The aspiration warning has a practical implication too: if you have a procedure requiring general anesthesia or deep sedation coming up, your anesthesiologist and surgical team need to know you are on a GLP-1 medication. That disclosure is on you and your prescriber, not on the pharmacy.

Why "Compounded Instead" Is Not a Workaround

A point that gets lost in a lot of online discussion: the contraindications attach to the molecule and the formulation, not to the brand name. If you have a personal or family history of MTC or MEN 2, that history does not become irrelevant because the semaglutide came from a compounding pharmacy rather than from a Wegovy carton. If you have had a serious hypersensitivity reaction to semaglutide, the same applies.

Compounded semaglutide is also not an FDA-approved finished product. Wegovy and Ozempic are the FDA-approved semaglutide brands; the FDA does not review compounded preparations for safety, effectiveness, or quality before they are marketed. A compounded preparation is dispensed by a licensed pharmacy pursuant to a prescription written for an individual patient — which is precisely why the prescribing step, and the medical history that informs it, still matters.

How Eligibility Actually Gets Decided

No website determines whether you should take Wegovy. A licensed prescriber does, after reviewing your personal and family medical history, your current medications, your other diagnoses, and — where relevant — your labs. The label gives that clinician the framework; your history supplies the facts.

What you can do is arrive prepared. Know whether thyroid cancer of any type runs in your family, and specifically whether anyone has been told they have medullary thyroid carcinoma or MEN 2. Know your history of pancreatitis, gallstones, kidney disease, and diabetic eye disease. Bring a complete medication list, including anything for diabetes. Mention any planned surgery. Those details are what turn a generic screening question into a real clinical assessment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Who is absolutely not allowed to take Wegovy?

The Wegovy label lists two contraindications. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone who has had a prior serious hypersensitivity reaction to semaglutide or to any excipient in the injection or tablet. Those are the only two absolute exclusions in the labeling.

Does a history of pancreatitis or gallstones disqualify me?

Not automatically. Acute pancreatitis and acute gallbladder disease appear in the warnings and precautions section, not in the contraindications section. That means they require careful evaluation and monitoring by a prescriber rather than ruling the medication out by default. Whether the benefit outweighs the risk in your case is a clinical judgment that depends on your full history.

Can I take Wegovy while pregnant or trying to conceive?

No. The label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that Wegovy be discontinued when a pregnancy is recognized for the weight-reduction indications. Novo Nordisk also maintains a pregnancy exposure registry for people exposed during pregnancy. Discuss pregnancy plans with your prescriber before starting, not after.

Can Wegovy be combined with another GLP-1 medication?

The label's Limitations of Use states that concomitant use of Wegovy tablets or injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. That covers combining a weight-management product with a diabetes product containing the same molecule, as well as pairing semaglutide with a different GLP-1 medication.

If Wegovy is not right for me, is compounded semaglutide an alternative?

Not if the reason is a contraindication. A history of medullary thyroid carcinoma, MEN 2, or serious hypersensitivity to semaglutide applies to the molecule regardless of where it was dispensed. Compounded semaglutide is also not an FDA-approved finished product and is not reviewed by the FDA for safety, effectiveness, or quality before marketing. Only a prescriber can assess suitable options.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.